The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Current challenges in treatment availability for multiple myeloma in Ireland
Ezzat El Hassadi, MD, University Hospital Waterford, Waterford, Ireland, highlights the current challenges in treatment opportunities for multiple myeloma in Ireland, including limited access to clinical trials and limited availability of immunotherapies. Dr El Hassadi also emphasizes the challenges related to treating patients who relapse after several lines of therapy or who experience central nervous system (CNS) relapse. Dr El Hassadi further comments on emerging side effects related to novel agents for myeloma, which poses an issue by limiting prolonged exposure to the drug. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
